Skip to Content

Join the 'Diabetic Macular Edema' group to help and get support from people like you.

Diabetic Macular Edema News

Related terms: DME

Routine Eye Exams See Vision Problems You Miss

Posted 14 Jul 2016 by Drugs.com

WEDNESDAY, July 13, 2016 – Routine eye checkups often pick up unnoticed problems, particularly in older adults, a new study says. "In asymptomatic patients, comprehensive routine optometric eye examinations detect a significant number of new eye conditions and/or results in management changes," said the study's author, Elizabeth Irving, and her colleagues from the University of Waterloo in Ontario, Canada. More than half of people with no new symptoms or vision problems receive new prescriptions or treatment changes as a result of routine eye exams, the researchers found. The need for vision prescription changes was found for two out of five people, the study noted. Meanwhile, 16 percent were diagnosed with a new eye condition and 31 percent had a change in their ongoing care, researchers found. The study included data on nearly 6,400 patients who visited a university eye clinic over ... Read more

Related support groups: Eye Conditions, Glaucoma, Cataract, Glaucoma (Open Angle), Macular Degeneration, Uveitis, Iritis, Keratitis, Optic Nerve Disorder, Ocular Herpes Simplex, Macular Edema, Corneal Abrasion, Retinal Disorders, Corneal Ulcer, Glaucoma/Intraocular Hypertension, Diagnosis and Investigation, Strabismus, Chorioretinitis, Glaucoma (Narrow Angle), Visual Defect/Disturbance

Experts Undecided on Whether Seniors Should Get Routine Vision Checks

Posted 1 Mar 2016 by Drugs.com

TUESDAY, March 1, 2016 – There's just not enough good data to say whether or not seniors should be routinely screened for vision trouble by their primary care physicians, an influential panel of U.S. experts reports. The U.S. Preventive Services Task Force (USPSTF) believes current data isn't adequate to assess the potential benefits and harms of such screening in people 65 or older. The task force is an independent, volunteer panel of experts that reviews the scientific evidence and makes recommendations on preventive health services. "We need more evidence on accurate ways to screen for eye conditions in older adults in a primary care setting," task force chair Dr. Al Siu said in a USPSTF news release. Siu is Mount Sinai Health System chair, and a professor in the department of geriatrics and palliative medicine at the Icahn School of Medicine at Mount Sinai, in New York City. ... Read more

Related support groups: Eye Conditions, Cataract, Macular Degeneration, Macular Edema, Diabetic Macular Edema, Visual Defect/Disturbance, Myopia, Color Vision Defect (Acquired)

Study Compares Drugs for Common Diabetic Eye Disease

Posted 29 Feb 2016 by Drugs.com

MONDAY, Feb. 29, 2016 – People with diabetes are at risk for blurred vision or even a loss of vision from a condition called macular edema. Three drugs for the disease – Avastin, Eylea and Lucentis – vary widely in price, but new research suggests all work equally well for patients with mild vision loss. However, when diabetic macular edema leads to more severe vision loss, researchers found Eylea to be the better choice. The study, funded by the U.S. National Eye Institute (NEI), "will help doctors and their patients with diabetic macular edema choose the most appropriate therapy," study lead author Dr. John Wells said in an institute news release. "The study suggests there is little advantage of choosing Eylea or Lucentis over [much cheaper] Avastin when a patient's loss of visual acuity from macular edema is mild, meaning a visual acuity of 20/40 or better," Wells explained. ... Read more

Related support groups: Eye Conditions, Macular Degeneration, Avastin, Diabetes Mellitus, Lucentis, Macular Edema, Eylea, Abnormal Glucose Tolerance, Bevacizumab, Diabetic Macular Edema, Visual Defect/Disturbance, Ranibizumab, Aflibercept

Carrots Do Help Aging Eyes, Study Shows

Posted 8 Oct 2015 by Drugs.com

THURSDAY, Oct. 8, 2015 – Your parents may have told you, "Eat your carrots, they're good for your eyes," and a new study suggests they were on to something. Pigments called carotenoids – which give red or orange hues to carrots, sweet potatoes and orange peppers, or deep greens to produce like spinach, broccoli and kale – may help ward off the age-linked vision ailment known as macular degeneration, researchers said. While the study can't prove cause-and-effect, one vision care expert wasn't surprised by the findings. "I tell my patients that fruit and vegetable consumption are very important for eye health – this study validates that notion," said Dr. Paul Bernstein, a professor of ophthalmology and visual sciences at the University of Utah School of Medicine in Salt Lake City. Age-related macular degeneration (AMD) is one of the most common causes of vision loss, especially in the ... Read more

Related support groups: Eye Conditions, Dietary Supplementation, Macular Degeneration, Macular Edema, Diabetic Macular Edema, Visual Defect/Disturbance, Carrot Oil

FDA Approves Eylea (aflibercept) for Diabetic Retinopathy in Patients with Diabetic Macular Edema

Posted 25 Mar 2015 by Drugs.com

March 25, 2015 – The U.S. Food and Drug Administration today expanded the approved use for Eylea (aflibercept) injection to treat diabetic retinopathy in patients with diabetic macular edema. Diabetic retinopathy (DR) is the most common diabetic eye disease and is a leading cause of blindness in adults in the United States. According to the Centers for Disease Control and Prevention, diabetes (type 1 and type 2) affects more than 29 million people in the United States and is the leading cause of new blindness among people ages 20 to 74 years. In 2008, 33 percent of adults with diabetes aged 40 years or older had some form of DR. In some cases of DR with diabetic macular edema (DME), abnormal new blood vessels grow on the surface of the retina. Severe vision loss or blindness can occur if the new blood vessels break. “Diabetes is a serious public health crisis, affecting more patients ... Read more

Related support groups: Eylea, Diabetic Retinopathy, Diabetic Macular Edema, Aflibercept

Study Compares Drugs for Diabetes-Linked Eye Disease

Posted 18 Feb 2015 by Drugs.com

WEDNESDAY, Feb. 18, 2015 – A vision-robbing condition called diabetic macular edema can strike people with diabetes. Now, a new study compared three leading drugs for the condition – Avastin, Eylea and Lucentis – and found that Eylea came out on top, at least for patients with "moderate" vision loss. The study, funded by the U.S. National Eye Institute (NEI), "will have a dramatic impact on patient care," said Dr. Mark Fromer, an ophthalmologist at Lenox Hill Hospital in New York City. He was not involved in the new research. According to the NEI, about 750,000 Americans suffer from diabetic macular edema. The condition occurs in people with a type of diabetes-related eye disease called diabetic retinopathy. "Diabetic macular edema is the most common reason for visual loss in the 7.7 million Americans with diabetic retinopathy," Fromer noted. "Macular edema occurs when abnormal blood ... Read more

Related support groups: Lucentis, Eylea, Diabetic Retinopathy, Diabetic Macular Edema, Retinopathy Prophylaxis

FDA Approves Revised Indication for Ozurdex for the Treatment of Diabetic Macular Edema

Posted 1 Oct 2014 by Drugs.com

IRVINE, Calif.-September 29, 2014 - Allergan, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved Ozurdex (dexamethasone intravitreal implant) 0.7 mg, a sustained-release biodegradable steroid implant, for the treatment of diabetic macular edema (DME). Ozurdex was originally approved in June as a treatment for DME in adult patients who have an artificial lens implant (pseudophakic) or who are scheduled for cataract surgery (phakic). Based on ongoing review of clinical data demonstrating efficacy and safety, the FDA has now approved Ozurdex for use in the general DME patient population. "Allergan is committed to developing innovative treatment options that address unmet patient needs, and retinal diseases such as DME are extremely difficult to manage," said Scott M. Whitcup, M.D., Executive Vice President, Research and Development and Chief Scientific ... Read more

Related support groups: Dexamethasone, Ozurdex, Diabetic Macular Edema

FDA Approves Iluvien for Diabetic Macular Edema

Posted 29 Sep 2014 by Drugs.com

WATERTOWN, Mass.--(BUSINESS WIRE)-- pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Iluvien for the treatment of diabetic macular edema (DME). It is indicated for patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). A single injection of the Iluvien micro-insert provides sustained treatment of DME for 36 months. Approximately 560,000 people in the U.S. are estimated to have clinically significant DME, the most frequent cause of vision loss in individuals with diabetes and the leading cause of blindness in young and middle-aged adults in developed countries. Iluvien is expected to be commercially available in the U.S. in early 2015. FDA approval ... Read more

Related support groups: Fluocinolone, Diabetic Macular Edema

Blacks May Face Higher Risk of Diabetes-Linked Vision Loss

Posted 21 Aug 2014 by Drugs.com

THURSDAY, Aug. 21, 2014 – Black Americans are at greater risk for diabetes-related vision loss than other racial groups battling the blood sugar disease, a new study says. Researchers analyzed data from the U.S. National Health and Nutrition Examination Survey, which evaluates about 5,000 people each year. They found that blacks had the highest rates of a condition known as diabetic macular edema – one of the leading causes of blindness in people with diabetes. Diabetic macular edema occurs when fluid and protein builds up in a part of the retina. This causes retinal swelling and a resulting loss of vision, the researchers explained. "We were surprised that our research showed that African Americans have the highest rates of diabetic macular edema, when Hispanics tend to have the highest prevalence of diabetes," study corresponding author Dr. Rohit Varma, director of the University of ... Read more

Related support groups: Diabetic Macular Edema

Eylea (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema

Posted 31 Jul 2014 by Drugs.com

TARRYTOWN, N.Y., July 29, 2014 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). The recommended dosage of Eylea in patients with DME is 2 milligrams (mg) every two months (8 weeks) after five initial monthly injections. Although Eylea may be dosed as frequently as 2 mg every 4 weeks, additional efficacy was not demonstrated when Eylea was dosed every 4 weeks compared to every 8 weeks. "Diabetic macular edema is a leading cause of vision loss among working-age adults in the U.S., and we are pleased to be able to offer a new treatment option to these patients," said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. "Our clinical studies have demonstrated ... Read more

Related support groups: Eylea, Diabetic Macular Edema, Aflibercept

Ask a Question

Further Information

Related Condition Support Groups

Macular Edema

Related Drug Support Groups

fluocinolone, Lucentis, Eylea, Ozurdex, Iluvien, ranibizumab, aflibercept